D STATES PATENT & TRADEMARK OFFICE

In re application of:

Applicants

Robert L. Gendron and

Paper No:

Helene Paradis

Serial No.

09/836,410

Group Art Unit:

1645

Filed:

April 17, 2001

: Examiner:

For:

INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE CDNA THERAPY

RESPONSE

THE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Dear Sir:

In response to the Office Action, dated June 4, 2001, please consider the following remarks.

Attached hereto, as requested by the Examiner, is a computer-readable disk of the sequence listings for the above patent application (prepared using PatentIn 3.1), as required by 37 C.F.R. 1.821(e). Additionally, corresponding hard-copy listings of these sequences are also enclosed.

I hereby state that the information recorded on said disk in computer-readable form is identical to the written sequence listing of the pending application. I further state that the submission made herein, filed in accordance with 37 CFR 1.821(g), does not include any new matter.

Respectfully submitted,

ROBERT L. GENDRON HELENE PARADIS

Dated: June 15, 2001

Karlyn A. Schnapp

Registration No. 45,558 Telephone (513) 651-6865

FROST BROWN TODD LLC

2200 PNC Center 201 East Fifth Street

Cincinnati, Ohio 45202-4182

Seria No. 09/836,410

CERTIFICATE OF MAILING

Lacen S. Frenkling

CINlibrary/1067651.1



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/836,410

04/17/2001

Robert L. Gendron

CONFIRMATION NO. 7267

FORMALITIES LETTER

OC000000006140765*

Frost Brown Todd LLC 2200 PNC Center 201 East Fifth Street Cincinnati, OH 45202

Date Mailed: 06/04/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821 (g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825 (b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspt .gov or patin3help@uspto.gov

Refund Ref: 08/02/2001 TLUU11

0000107847

CHECK Refund Total:

\$65.00



A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE